>SHOULDITAKEIT
SearchSign In
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
NOT MEDICAL ADVICE - FOR EDUCATIONAL PURPOSES ONLY
Back to peptides
PEPTIDE

Retatrutide

Retatrutide is a novel triple-agonist peptide developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It activates GLP-1, GIP, and glucagon receptors together for synergistic metaboli...

Type

Peptide

Mol. Weight

~4.5 kDa

Half-Life

~6 days

Routes

1 method

Retatrutide is a novel triple-agonist peptide developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It represents a significant advancement in metabolic therapeutics by simultaneously targeting three key hormone receptors.

Unlike single or dual-agonist medications, Retatrutide activates GLP-1, GIP, and glucagon receptors together, creating a synergistic effect that addresses multiple aspects of metabolic dysfunction.